Drug and Therapeutics Bulletin 1999;37:47-48; doi:10.1136/dtb.1999.37647
Copyright © 1999 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Tazarotene - a topical retinoid for psoriasis

Relevant BNF section: 13.5.2

Retinoids have been given systemically for severe psoriasis for several years.1 {blacktriangledown}Tazarotene (Zorac - Allergan), the first retinoid to be marketed as a topical preparation for psoriasis, was recently licensed for mild-to-moderate plaque psoriasis involving up to 10% of the body surface area. Here we assess its place in the management of psoriasis.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1999 BMJ Publishing Group Ltd.